Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

KRRO

Korro Bio Inc.

Sep 20 • 04:00PM ET

36.33

Dollar change -2.17
Percentage change -5.64	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN VTWO VHT IWO IWC ITOT VTWV

Index	RUT	P/E	-	EPS (ttm)	-25.49	Insider Own	36.37%	Shs Outstand	8.02M	Perf Week	-12.31%
Market Cap	337.87M	Forward P/E	-	EPS next Y	-9.79	Insider Trans	5.57%	Shs Float	5.92M	Perf Month	-21.06%
Income	-92.22M	PEG	-	EPS next Q	-2.55	Inst Own	62.88%	Short Float	4.86%	Perf Quarter	2.69%
Sales	0.00M	P/S	-	EPS this Y	82.24%	Inst Trans	-28.19%	Short Ratio	3.31	Perf Half Y	-44.11%
Book/sh	21.34	P/B	1.70	EPS next Y	-3.86%	ROA	-56.06%	Short Interest	0.29M	Perf Year	267.90%
Cash/sh	17.12	P/C	2.12	EPS next 5Y	-	ROE	-75.75%	52W Range	4.57 - 97.91	Perf YTD	-24.20%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-11.67%	ROI	-39.06%	52W High	-62.89%	Beta	3.85
Dividend TTM	-	Quick Ratio	13.28	Sales past 5Y	-26.84%	Gross Margin	-	52W Low	694.10%	ATR (14)	4.27
Dividend Ex-Date	-	Current Ratio	13.28	EPS Y/Y TTM	73.20%	Oper. Margin	0.00%	RSI (14)	38.69	Volatility	10.28% 10.33%
Employees	101	Debt/Eq	0.19	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	123.75
Option/Short	No / Yes	LT Debt/Eq	0.19	EPS Q/Q	83.89%	Payout	-	Rel Volume	1.78	Prev Close	38.50
Sales Surprise	-	EPS Surprise	-0.06%	Sales Q/Q	-	Earnings	Aug 13 AMC	Avg Volume	86.90K	Price	36.33
SMA20	-15.51%	SMA50	-16.86%	SMA200	-29.08%	Trades		Volume	154,288	Change	-5.64%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-14-24	Initiated	William Blair	Outperform	$180
Mar-28-24	Reiterated	H.C. Wainwright	Buy	$100 → $115
Feb-27-24	Initiated	BMO Capital Markets	Outperform	$120
Dec-04-23	Initiated	H.C. Wainwright	Buy	$100
Nov-29-23	Initiated	RBC Capital Mkts	Outperform	$70
Nov-10-23	Initiated	Piper Sandler	Overweight	$180
Feb-15-23	Downgrade	Chardan Capital Markets	Buy → Neutral
Feb-13-23	Downgrade	Cowen	Outperform → Market Perform
Sep-22-21	Downgrade	Goldman	Buy → Neutral	$12 → $9
Jan-27-21	Upgrade	JP Morgan	Neutral → Overweight	$56
Dec-22-20	Initiated	B. Riley Securities	Buy	$79
Jul-14-20	Initiated	Oppenheimer	Outperform	$36
May-18-20	Downgrade	JP Morgan	Overweight → Neutral	$27
Oct-28-19	Initiated	JP Morgan	Overweight	$25
Oct-28-19	Initiated	Goldman	Buy	$30
Oct-28-19	Initiated	Cowen	Outperform

Show Previous Ratings

Sep-16-24 08:00AM	Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates (GlobeNewswire)
Sep-10-24 08:00AM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-28-24 08:00AM	Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors (GlobeNewswire)
Aug-27-24 08:00AM	Korro to Participate in Upcoming September Investor and Scientific Conferences (GlobeNewswire)
Aug-13-24 04:01PM	Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) +9.21%
08:00AM	Loading…
Jul-01-24 08:00AM	Korro Joins the Russell 2000 , Russell 3000 , and Russell Microcap Indexes (GlobeNewswire)
Jun-25-24 12:53PM	KRRO Stock Earnings: Korro Bio Beats EPS for Q4 2023 (InvestorPlace)
May-30-24 04:01PM	Korro to Participate in Upcoming June Investor and Scientific Conferences (GlobeNewswire)
May-20-24 02:30PM	Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference (GlobeNewswire)
May-14-24 10:55PM	KRRO Stock Earnings: Korro Bio Beats EPS for Q1 2024 (InvestorPlace) +5.43%
04:01PM	Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer (GlobeNewswire)
Apr-18-24 08:30AM	Korro Announces $70 Million Private Placement (GlobeNewswire)
Apr-01-24 04:01PM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.90%
Mar-26-24 04:01PM	Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress (GlobeNewswire) +18.43%
Feb-27-24 09:55AM	Wall Street Analysts Believe Korro Bio, Inc. (KRRO) Could Rally 86.94%: Here's is How to Trade (Zacks) -6.08%
08:00AM	Loading…
08:00AM	Korro to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-09-24 09:55AM	Does Korro Bio, Inc. (KRRO) Have the Potential to Rally 59.66% as Wall Street Analysts Expect? (Zacks)
Jan-18-24 08:00AM	Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio (GlobeNewswire) -5.98%
Jan-04-24 08:00AM	Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-07-23 08:00AM	Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire) -14.67%
Nov-28-23 08:00AM	Korro Bio Appoints Dr. Rachel Meyers to Board of Directors (GlobeNewswire) +6.45%
Nov-03-23 03:31PM	UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million (GlobeNewswire) +5.94%
12:19PM	Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million (GlobeNewswire)
Aug-10-23 04:01PM	Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results (Business Wire)
Jul-17-23 11:59AM	Frequency (FREQ) Up 77% on Merger Deal With Korro Bio (Zacks) -12.66%
Jul-14-23 11:22AM	Why Are Frequency Therapeutics Shares Surging Today (Benzinga) +77.47%
06:30AM	Korro Bio and Frequency Therapeutics Announce Merger Agreement (Business Wire)
May-12-23 04:01PM	Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results (Business Wire) -5.17%
Mar-10-23 07:30AM	Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Feb-27-23 07:30AM	Frequency Therapeutics to Participate at Upcoming March Investor Conferences (Business Wire) +5.40%
01:55PM	Loading…
Feb-13-23 01:55PM	Hearing loss startup to cut more than half of staff in wake of trial failure (American City Business Journals) -80.54%
11:17AM	Frequency Therapeutics' Lead Hearing Loss Program Flunks, Shifts Focus To Multiple Sclerosis, Shares Plunge (Benzinga)
08:05AM	Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss (Business Wire)
Dec-19-22 07:30AM	Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program (Business Wire)
Dec-15-22 07:30AM	Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Companys Second Therapeutic Candidate for Sensorineural Hearing Loss (Business Wire)
Nov-17-22 07:30AM	Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results (Business Wire) -10.05%
Nov-08-22 04:05PM	Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results (Business Wire) -9.51%
Oct-12-22 07:30AM	Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss (Business Wire) +7.47%
Aug-30-22 07:30AM	Frequency Therapeutics to Participate in September Investor and Medical Conferences (Business Wire)
Aug-09-22 04:05PM	Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results (Business Wire) -11.11% +9.00%
Jun-24-22 09:03AM	Frequency Therapeutics (NASDAQ:FREQ) one-year losses have grown faster than shareholder returns have fallen, but the stock jumps 41% this past week (Simply Wall St.) -7.59%
May-25-22 12:00PM	Frequency Therapeutics, Inc. (FREQ) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
May-18-22 07:30AM	Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference (Business Wire) -9.02%
May-04-22 04:30PM	Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results (Business Wire)
Apr-22-22 07:30AM	Frequency Therapeutics to Participate in B. Riley Securities Neuro & Ophthalmology Investor Conference (Business Wire)
Apr-08-22 05:00PM	Frequency Exchange Corp. Virtually Closes the Market (PR Newswire) -8.82%
Mar-15-22 07:30AM	Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results (Business Wire) +15.29%
Mar-10-22 06:35PM	Poseida Therapeutics, Inc. (PSTX) Beats Q4 Earnings and Revenue Estimates (Zacks) -13.70%
Feb-28-22 07:30AM	Frequency Therapeutics to Participate in Upcoming March 2022 Investor Conferences (Business Wire)
Jan-14-22 05:43AM	One Frequency Therapeutics, Inc. (NASDAQ:FREQ) insider upped their stake in the previous year (Simply Wall St.)
Jan-04-22 07:30AM	Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-28-21 02:38AM	Destra Investment Trust Buys ThredUp Inc, Etsy Inc, Riskified, Sells , , 2U Inc (GuruFocus.com) +5.28%
Dec-09-21 01:18PM	Frequency Therapeutics' Hearing Loss Candidate Shows Improved Speech Perception In Noise (Benzinga)
07:30AM	Frequency Therapeutics Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise (Business Wire)
Nov-30-21 05:53AM	Frequency Therapeutics (NASDAQ:FREQ) investors are sitting on a loss of 81% if they invested a year ago (Simply Wall St.)
Nov-15-21 12:25PM	Frequency Therapeutics, Inc. (FREQ) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results (Business Wire)
Nov-09-21 07:30AM	Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in Multiple Sclerosis (Business Wire)
Nov-08-21 03:00PM	Analysts Estimate Frequency Therapeutics, Inc. (FREQ) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-27-21 07:30AM	Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration and In Vivo Data from its MS Remyelination Program (Business Wire)
Oct-21-21 07:30AM	Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint (Business Wire)
Oct-01-21 08:23AM	Do Insiders Own Lots Of Shares In Frequency Therapeutics, Inc. (NASDAQ:FREQ)? (Simply Wall St.)
Sep-22-21 11:18AM	Frequency Therapeutics' New Data Of Hearing Loss Candidate Fails To Impress Investors (Benzinga)
07:30AM	Frequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improvements at Later Time Points (Business Wire)
Sep-08-21 07:30AM	Frequency Therapeutics to Present at Upcoming Investor Conferences (Business Wire)
Aug-30-21 05:10PM	Lifshitz Law Firm, P.C. Announces Investigations of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Frequency Therapeutics, Inc. (NasdaqGS: FREQ), RLX Technology Inc. (NYSE: RLX), and Washington Prime Group, Inc. (NYSE: WPG) (ACCESSWIRE)
Aug-12-21 04:06PM	Moore Kuehn, PLLC Encourages Investors of FREQ to Contact Law Firm (Newsfile)
08:45AM	Frequency Therapeutics, Inc. (FREQ) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Frequency Therapeutics Provides Business Updates and Second Quarter 2021 Financial Results (Business Wire)
Aug-04-21 03:00PM	Analysts Estimate Frequency Therapeutics, Inc. (FREQ) to Report a Decline in Earnings: What to Look Out for (Zacks)
Aug-02-21 03:05PM	CLASS ACTION UPDATE for JRVR, FREQ and QFIN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders (ACCESSWIRE)
02:30PM	Final Deadline Alert: Frequency Therapeutics, Inc. (FREQ) Class Action and Last Chance for Investors to Actively Participate - Bronstein, Gewirtz & Grossman, LLC (ACCESSWIRE)
12:30PM	SHAREHOLDER ALERT: FREQ RKT QFIN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines (ACCESSWIRE)
12:30PM	FINAL DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (ACCESSWIRE)
11:00AM	FREQ Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Frequency Therapeutics, Inc. (FREQ) Shareholders of Class Action and Lead Plaintiff Deadline: August 2, 2021 (ACCESSWIRE)
10:00AM	The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FREQ, RKT and BZ (ACCESSWIRE)
09:16AM	FREQ Final Deadline Today: Rosen, National Trial Lawyers, Encourages Frequency Therapeutics, Inc. Investors to Secure Counsel Before Important August 2 Deadline in Securities Class Action - FREQ (Newsfile)
09:09AM	DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (Newsfile)
05:50AM	The Gross Law Firm Announces Class Actions on Behalf of Shareholders of FREQ, RLX and DIDI (ACCESSWIRE)
03:27AM	Frequency Therapeutics (NASDAQ:FREQ) Has Debt But No Earnings; Should You Worry? (Simply Wall St.)
Aug-01-21 10:38AM	FREQUENCY DEADLINE ALERT: Faruqi & Faruqi LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Frequency To Contact Him Directly To Discuss Their Options (GlobeNewswire)
06:36AM	FREQ FINAL DEADLINE: ROSEN, A TOP RANKED FIRM, Encourages Frequency Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline Tomorrow in Securities Class Action - FREQ (Newsfile)
Jul-30-21 08:49PM	DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Frequency Therapeutics, Inc. and Encourages Investors to Contact the Firm (Business Wire)
07:19PM	Frequency Therapeutics, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm (GlobeNewswire)
07:10PM	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Frequency Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - FREQ (ACCESSWIRE)
05:15PM	FREQ Final Deadline Monday: Rosen, Leading Trial Attorneys, Encourages Frequency Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important August 2 Deadline in Securities Class Action - FREQ (Newsfile)
02:57PM	FREQ LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Frequency Therapeutics, Inc. (Newsfile)
01:30PM	FINAL DEADLINE IMMINENT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (ACCESSWIRE)
12:40PM	The Gross Law Firm Announces Class Actions on Behalf of Shareholders of FREQ, OCGN and BLCT (ACCESSWIRE)
11:30AM	The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Frequency Therapeutics, Inc. (FREQ) (Business Wire)
11:30AM	CLASS ACTION UPDATE for CCIV, FREQ and RLX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders (ACCESSWIRE)
11:00AM	FREQ INVESTOR ALERT: Shareholder Lawsuit Deadline Approaching (ACCESSWIRE)
10:00AM	SHAREHOLDER ALERT: FREQ RLX DIDI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines (ACCESSWIRE)
10:00AM	FREQ Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Frequency Therapeutics, Inc. (FREQ) Shareholders of Class Action and Lead Plaintiff Deadline: August 2, 2021 (GlobeNewswire)
09:30AM	MONDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (Newsfile)
09:00AM	FREQUENCY THERAPEUTICS SHAREHOLDERS: August 2, 2021 Filing Deadline in Class Action - Contact Lieff Cabraser (ACCESSWIRE)
05:18AM	FREQ ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 2, 2021 in the Class Action Filed on Behalf of Frequency Therapeutics, Inc. Limited Shareholders (Newsfile)
Jul-29-21 08:47PM	Frequency Class Action Reminder (Newsfile)
05:29PM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Frequency Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 2, 2021 - FREQ (Newsfile)
04:02PM	MONDAY DEADLINE: Investors with Substantial Losses Have Opportunity to Lead the Frequency Therapeutics, Inc. Class Action Lawsuit - FREQ (PR Newswire)

Korro Bio, Inc. is an RNA editing company, which engages in the discovery and development of genetic medicines. The company was founded by Nessan Bermingham, Jean-Francois Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Colletti Steve	Former Officer	Aug 30 '24	Proposed Sale	49.24	10,303	507,326		Aug 30 05:28 PM
New Enterprise Associates 17,	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
BASKETT FOREST	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Florence Anthony A. Jr.	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Walker Paul Edward	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Chang Carmen	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Mathers Edward T	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Yang Rick	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Makhzoumi Mohamad	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
SANDELL SCOTT D	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Atlas Venture Opportunity Fund	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	195,074	Apr 23 05:23 PM
Lucchino David L.	Director	Nov 22 '23	Sale	37.69	1,156	43,573	22,150	Nov 27 08:48 PM
Lucchino David L.	Director	Nov 10 '23	Sale	41.97	968	40,632	23,306	Nov 22 04:05 PM

Open in Screener

DYN

Dyne Therapeutics Inc

Sep 20 • 04:00PM ET

36.59

Dollar change +0.18
Percentage change 0.49	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

DYN Dyne Therapeutics Inc daily Stock Chart

Held by: VTI IWM XBI VXF IWO IBB VTWO SCHA VHT DWAS

Index	RUT	P/E	-	EPS (ttm)	-3.58	Insider Own	25.28%	Shs Outstand	100.40M	Perf Week	7.43%
Market Cap	3.67B	Forward P/E	-	EPS next Y	-3.11	Insider Trans	-7.59%	Shs Float	75.02M	Perf Month	-22.22%
Income	-257.60M	PEG	-	EPS next Q	-0.70	Inst Own	84.32%	Short Float	9.15%	Perf Quarter	4.48%
Sales	0.00M	P/S	-	EPS this Y	24.64%	Inst Trans	-2.76%	Short Ratio	5.19	Perf Half Y	25.39%
Book/sh	7.74	P/B	4.73	EPS next Y	-4.56%	ROA	-47.82%	Short Interest	6.87M	Perf Year	292.60%
Cash/sh	7.76	P/C	4.72	EPS next 5Y	-	ROE	-52.46%	52W Range	6.40 - 47.45	Perf YTD	175.11%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-106.26%	ROI	-32.36%	52W High	-22.89%	Beta	1.07
Dividend TTM	-	Quick Ratio	26.63	Sales past 5Y	0.00%	Gross Margin	-	52W Low	471.72%	ATR (14)	2.39
Dividend Ex-Date	-	Current Ratio	26.63	EPS Y/Y TTM	-5.17%	Oper. Margin	0.00%	RSI (14)	46.36	Volatility	3.94% 6.57%
Employees	141	Debt/Eq	0.03	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	53.00
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	35.12%	Payout	-	Rel Volume	2.58	Prev Close	36.41
Sales Surprise	-	EPS Surprise	2.45%	Sales Q/Q	-	Earnings	Aug 12 AMC	Avg Volume	1.32M	Price	36.59
SMA20	-2.95%	SMA50	-10.94%	SMA200	27.43%	Trades		Volume	3,412,947	Change	0.49%

Date	Action	Analyst	Rating Change	Price Target Change
May-21-24	Reiterated	Chardan Capital Markets	Buy	$31 → $42
Apr-30-24	Initiated	Morgan Stanley	Overweight	$40
Feb-20-24	Initiated	H.C. Wainwright	Buy	$36
Feb-27-23	Upgrade	Raymond James	Outperform → Strong Buy	$16 → $27
Feb-15-23	Initiated	Oppenheimer	Outperform	$34
Jan-26-23	Initiated	Guggenheim	Buy	$33
Jul-20-22	Initiated	Chardan Capital Markets	Buy	$17
Jul-12-22	Initiated	Raymond James	Outperform	$15
Oct-12-20	Initiated	Stifel	Buy	$29
Oct-12-20	Initiated	Piper Sandler	Overweight	$34
Oct-12-20	Initiated	JP Morgan	Overweight	$27
Oct-12-20	Initiated	Jefferies	Buy	$47

Show Previous Ratings

Sep-04-24 09:10AM	Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Shares Dive On C-Suite Changes (Investor's Business Daily) +5.70%
08:15AM	High-dose Spinraza meets study goal; Top Dyne executives exit (BioPharma Dive)
Sep-03-24 12:37PM	Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy (Benzinga) -30.70%
06:31AM	Dyne Therapeutics Announces Key Leadership Appointments (GlobeNewswire)
06:30AM	Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts (GlobeNewswire)
07:30AM	Loading…
Aug-29-24 07:30AM	Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-12-24 10:52PM	DYN Stock Earnings: Dyne Therapeutics Beats EPS for Q2 2024 (InvestorPlace)
05:10PM	Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-29-24 08:50AM	Recent Price Trend in Dyne Therapeutics (DYN) is Your Friend, Here's Why (Zacks)
Jul-18-24 12:00PM	What Makes Dyne Therapeutics, Inc. (DYN) a Strong Momentum Stock: Buy Now? (Zacks)
Jul-12-24 08:50AM	Dyne Therapeutics (DYN) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Jun-24-24 07:30AM	Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease (GlobeNewswire)
Jun-13-24 04:40PM	Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress (GlobeNewswire)
Jun-04-24 06:00AM	The 3 Most Undervalued Biotech Stocks to Buy in June 2024 (InvestorPlace)
May-30-24 07:30AM	Dyne Therapeutics to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
07:30AM	Loading…
May-28-24 07:30AM	Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire)
May-21-24 08:39PM	Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock (GlobeNewswire) -7.77%
12:27PM	Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies (Zacks)
07:17AM	Chardan Raises Price Target on Dyne Therapeutics to $42 From $31, Cites Additional Positive Data on DYNE-101, DYNE-251; Buy Rating Kept (MT Newswires)
May-20-24 05:53PM	Why Is Dyne Therapeutics Stock Soaring On Monday? (Benzinga) +27.82%
04:27PM	Dyne Therapeutics Launches $300 Million Share Offering (MT Newswires)
04:07PM	Why Dyne Therapeutics, With A 166% Run This Year, Just Catapulted Again (Investor's Business Daily)
04:01PM	Dyne Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
11:22AM	Update: Dyne Shares Rise After Trial Data of DYNE-101, DYNE-251 Showed Improvements in Functional Endpoints, Favorable Safety Profiles (MT Newswires)
09:40AM	HC Wainwright Adjusts Price Target on Dyne Therapeutics to $48 From $46, Maintains Buy Rating (MT Newswires)
09:12AM	Sector Update: Health Care Stocks Mixed Pre-Bell Monday (MT Newswires)
08:02AM	Dyne shares jump on trial data for muscle disease drugs (BioPharma Dive)
07:47AM	Dyne Says Trial Data of DYNE-101, DYNE-251 Showed Improvements in Functional Endpoints, Favorable Safety Profiles (MT Newswires)
07:36AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
06:30AM	Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints (GlobeNewswire)
08:00AM	Loading…
May-19-24 08:00AM	Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET (GlobeNewswire)
May-04-24 05:31AM	Dyne Therapeutics Inc (DYN) Q1 2024 Earnings: Aligns with Analyst Projections (GuruFocus.com)
May-02-24 11:52PM	DYN Stock Earnings: Dyne Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
04:10PM	Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-30-24 07:32AM	Morgan Stanley Starts Dyne Therapeutics With Overweight Rating, $40 Price Target (MT Newswires)
Mar-27-24 04:05PM	Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer (GlobeNewswire) +6.42%
08:30AM	Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium (GlobeNewswire)
Mar-25-24 12:28PM	United Airlines, Dyne Therapeutics fall; Lucid Group, Century Aluminum rise, Monday, 3/25/2024 (Associated Press Finance) -7.72%
07:30AM	Dyne Therapeutics Announces CEO Transition (GlobeNewswire)
Mar-13-24 07:30AM	Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days (GlobeNewswire)
Mar-07-24 01:19PM	Dyne Therapeutics Inc (DYN) Reports Encouraging Clinical Data and Financial Growth for Q4 and ... (GuruFocus.com)
Mar-05-24 10:53AM	DYN Stock Earnings: Dyne Therapeutics Misses EPS for Q4 2023 (InvestorPlace) -6.64%
07:30AM	Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-02-24 12:00AM	CEO & President Joshua Brumm Sells 100,000 Shares of Dyne Therapeutics Inc (DYN) (GuruFocus.com)
Feb-29-24 03:02AM	14 Stocks With Heavy Insider Buying In 2024 (Insider Monkey) +7.69%
Feb-14-24 04:15PM	Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference (GlobeNewswire)
Feb-01-24 07:30AM	Dyne Therapeutics to Present at February Investor Conferences (GlobeNewswire)
Jan-26-24 11:01PM	Chief Business Officer Jonathan Mcneill Sells 20,000 Shares of Dyne Therapeutics Inc (DYN) (GuruFocus.com) +18.21%
Jan-22-24 10:14PM	7 Speculative Stocks to Double Your Money THIS Year (InvestorPlace)
Jan-12-24 01:12PM	Hedge Fund and Insider Trading News: Steve Cohen, Crispin Odey, Bill Ackman, Saba Capital Management, Moab Capital Partners, Eisler Capital, Dyne Therapeutics Inc. (DYN), and More (Insider Monkey)
Jan-11-24 04:05PM	Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire) -5.36%
Jan-05-24 09:02AM	CEO & President Joshua Brumm Sells 269,719 Shares of Dyne Therapeutics Inc (DYN) (GuruFocus.com) -7.37%
07:30AM	Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-04-24 10:46PM	Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock (GlobeNewswire) +31.28%
04:37PM	Todays Stock Market Movers: Walgreens, Mobileye, Apple, APA, Callon, Peloton, Sunrun, and More (Barrons.com)
12:39PM	These Stocks Are Moving the Most Today: Walgreens, Mobileye, Apple, APA, Callon, Peloton, Sunrun, and More (Barrons.com)
Jan-03-24 04:25PM	Dyne Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +13.09%
02:46PM	Biotech Stocks Dyne, Agios Leap on Muscle-Disorder Drugs' Trial Results (The Wall Street Journal)
02:01PM	Biotechs Dyne, Agios Leap on Muscle-Disorder Drugs Trial Results (The Wall Street Journal)
08:19AM	Why Is Dyne Therapeutics (DYN) Stock Up 39% Today? (InvestorPlace)
06:30AM	Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE Platform in Developing Therapeutics for Rare Muscle Diseases (GlobeNewswire)
Jan-02-24 04:05PM	Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials (GlobeNewswire)
Nov-13-23 06:59PM	3 of the Best Cheap Stocks Under $20 to Buy Now: November Edition (InvestorPlace) +18.97%
Nov-07-23 07:30AM	Dyne Therapeutics to Present at November Investor Conferences (GlobeNewswire) +14.58%
Oct-31-23 05:36AM	Dyne Therapeutics Inc (DYN) Reports Q3 2023 Financial Results and Progress in Clinical Trials (GuruFocus.com)
01:11AM	The Dyne Therapeutics Inc (DYN) Company: A Short SWOT Analysis (GuruFocus.com)
Oct-30-23 07:30AM	Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones (GlobeNewswire) +10.57%
Sep-28-23 07:30AM	Dyne Therapeutics to Present at October Investor Conferences (GlobeNewswire)
Sep-20-23 04:05PM	Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1 (GlobeNewswire) -5.48%
Sep-15-23 01:52PM	Why Shares of Dyne Therapeutics Fell This Week (Motley Fool)
Sep-14-23 01:22PM	Insider Sell: Chief Medical Officer Wildon Farwell Sells 1,707 Shares of Dyne Therapeutics Inc (GuruFocus.com)
Sep-05-23 07:30AM	Dyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-28-23 10:22AM	15 Most Shorted Stocks That Are Loved By Analysts (Insider Monkey)
Aug-03-23 07:30AM	Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Jun-16-23 08:46AM	SMID Caps Are Poised for a Good Run, Says Oppenheimer And These 2 Stocks Fit the Bill With Over 100% Upside (TipRanks) -9.50%
Jun-01-23 07:30AM	Dyne Therapeutics to Present at Jefferies Healthcare Conference (GlobeNewswire)
May-25-23 07:30AM	Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101 (GlobeNewswire) -7.56%
May-17-23 11:25AM	We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate (Simply Wall St.)
07:30AM	Dyne Therapeutics Preclinical Data Demonstrating FORCE Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual Meeting (GlobeNewswire)
May-11-23 07:30AM	Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
May-03-23 07:35AM	Dyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference (GlobeNewswire)
May-02-23 04:46PM	Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE Platform Delivery to CNS (GlobeNewswire)
Mar-23-23 07:30AM	Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Mar-20-23 07:30AM	Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference (GlobeNewswire)
Mar-07-23 07:30AM	Dyne Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Mar-02-23 07:30AM	Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (GlobeNewswire) +5.06%
Mar-01-23 09:00AM	How to chart anchored VWAP multiple time frames: Brian Shannon, CMT (Yahoo Finance Video) +5.82%
Feb-27-23 04:40PM	Analyst Says This Small Cap Biotech Firm Has 'Very Valuable Therapeutic,' Upgrades Stock (Benzinga) +12.76%
Feb-05-23 05:03AM	TipRanks Perfect 10 List: Strong Catalysts Confirm the Bull Thesis on These 2 Stocks (TipRanks)
Jan-19-23 08:23AM	Zacks Industry Outlook Highlights Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics (Zacks)
Jan-18-23 08:49AM	5 Stocks to Buy as the Drug Industry Bets Big on Innovation (Zacks)
Jan-10-23 12:00PM	All You Need to Know About Dyne Therapeutics, Inc. (DYN) Rating Upgrade to Strong Buy (Zacks)
Jan-03-23 07:30AM	Dyne Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-22 09:55AM	Does Dyne Therapeutics, Inc. (DYN) Have the Potential to Rally 84% as Wall Street Analysts Expect? (Zacks)
Dec-09-22 09:55AM	Here's Why Dyne Therapeutics, Inc. (DYN) Is a Great 'Buy the Bottom' Stock Now (Zacks) -5.05%
Dec-08-22 08:10AM	Will Dyne Therapeutics (NASDAQ:DYN) Spend Its Cash Wisely? (Simply Wall St.)
Nov-30-22 09:55AM	Wall Street Analysts Predict a 141% Upside in Dyne Therapeutics, Inc. (DYN): Here's What You Should Know (Zacks) +8.43%
Nov-03-22 07:30AM	Dyne Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights (GlobeNewswire) +9.63%
Nov-02-22 07:30AM	Dyne Therapeutics to Present at Investor Conferences in November (GlobeNewswire)
Oct-31-22 07:30AM	Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kersten Dirk	Director	Sep 19 '24	Sale	36.17	78,739	2,848,283	313,538	Sep 20 04:05 PM
Kersten Dirk	Director	Sep 18 '24	Sale	35.03	1,554	54,437	392,277	Sep 20 04:05 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Sep 18 '24	Sale	34.41	8,976	308,864	131,636	Sep 19 04:52 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Sep 18 '24	Sale	34.55	1,390	48,024	98,568	Sep 19 04:52 PM
Beskrovnaya Oxana	Chief Scientific Officer	Sep 18 '24	Sale	34.55	2,339	80,812	140,375	Sep 19 04:51 PM
Scalzo Richard William	Officer	Sep 18 '24	Proposed Sale	34.51	1,390	47,964		Sep 18 04:24 PM
Beskrovnaya Oxana	Officer	Sep 18 '24	Proposed Sale	34.51	2,339	80,715		Sep 18 04:23 PM
McNeill Jonathan	Officer	Sep 18 '24	Proposed Sale	34.51	1,870	64,528		Sep 18 04:21 PM
HIGH SUSANNA GATTI	Officer	Sep 18 '24	Proposed Sale	34.41	8,967	308,512		Sep 18 04:20 PM
Kersten Dirk	Director	Sep 17 '24	Sale	35.13	3,272	114,945	393,831	Sep 18 04:05 PM
Kersten Dirk	Director	Sep 16 '24	Sale	35.04	1,320	46,253	397,103	Sep 18 04:05 PM
Farwell Wildon	Officer	Sep 11 '24	Proposed Sale	32.43	2,645	85,777		Sep 11 04:36 PM
HIGH SUSANNA GATTI	Officer	Sep 11 '24	Proposed Sale	32.43	5,270	170,906		Sep 11 04:34 PM
Scalzo Richard William	Officer	Sep 11 '24	Proposed Sale	32.43	1,468	47,607		Sep 11 04:31 PM
Beskrovnaya Oxana	Officer	Sep 11 '24	Proposed Sale	32.43	2,161	70,081		Sep 11 04:28 PM
McNeill Jonathan	Officer	Sep 11 '24	Proposed Sale	32.43	1,823	59,120		Sep 11 04:26 PM
Beskrovnaya Oxana	Chief Scientific Officer	Sep 11 '24	Sale	31.89	2,161	68,914	142,714	Sep 11 04:13 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Sep 11 '24	Sale	31.89	1,468	46,815	99,958	Sep 11 04:13 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Sep 11 '24	Sale	31.89	5,270	168,060	140,612	Sep 11 04:13 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Sep 06 '24	Option Exercise	12.56	116,478	1,463,376	227,500	Sep 10 04:05 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Sep 06 '24	Sale	32.15	126,074	4,052,851	101,426	Sep 10 04:05 PM
Kersten Dirk	Director	Sep 05 '24	Sale	35.03	1,577	55,242	398,423	Sep 09 04:05 PM
Scalzo Richard William	Officer	Aug 19 '24	Proposed Sale	33.65	126,073	4,242,356		Sep 06 04:22 PM
McNeill Jonathan	Officer	Sep 05 '24	Proposed Sale	33.61	166,767	5,605,442		Sep 05 04:34 PM
Cox John	CEO & President	Sep 04 '24	Buy	33.04	32,000	1,057,216	8,000	Sep 04 05:42 PM
Kersten Dirk	Director	Aug 30 '24	Sale	45.59	31,300	1,427,063	400,000	Sep 04 04:05 PM
Kersten Dirk	Director	Aug 28 '24	Sale	44.83	77,853	3,490,029	487,708	Aug 30 04:05 PM
Kersten Dirk	Director	Aug 29 '24	Sale	45.31	56,408	2,555,754	431,300	Aug 30 04:05 PM
Kersten Dirk	Director	Aug 26 '24	Sale	45.30	89,497	4,054,408	630,964	Aug 28 04:05 PM
Kersten Dirk	Director	Aug 27 '24	Sale	44.28	65,403	2,896,045	565,561	Aug 28 04:05 PM
Kersten Dirk	Director	Aug 22 '24	Sale	45.82	95,321	4,368,083	805,549	Aug 26 04:05 PM
Kersten Dirk	Director	Aug 23 '24	Sale	46.23	85,088	3,934,005	720,461	Aug 26 04:05 PM
Kersten Dirk	Director	Aug 21 '24	Sale	46.78	135,763	6,350,605	900,870	Aug 22 04:05 PM
Kersten Dirk	Director	Aug 20 '24	Sale	46.35	86,840	4,025,015	1,036,633	Aug 22 04:05 PM
Forbion Capital Fund IV Cooper	Affiliate	Aug 21 '24	Proposed Sale	46.48	1,025,000	47,642,000		Aug 21 04:02 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Aug 19 '24	Sale	45.12	2,752	124,174	111,022	Aug 20 04:28 PM
McNeill Jonathan	Chief Business Officer	Aug 19 '24	Sale	45.12	2,705	122,054	132,106	Aug 20 04:27 PM
Farwell Wildon	Chief Medical Officer	Aug 19 '24	Sale	45.12	2,321	104,727	143,222	Aug 20 04:27 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Aug 19 '24	Sale	45.12	2,910	131,304	145,882	Aug 20 04:26 PM
Beskrovnaya Oxana	Chief Scientific Officer	Aug 19 '24	Sale	45.12	2,636	118,939	144,875	Aug 20 04:26 PM
Kersten Dirk	Director	Aug 19 '24	Sale	45.82	126,032	5,774,365	1,123,473	Aug 20 04:05 PM
Kersten Dirk	Director	Aug 16 '24	Sale	45.14	122,643	5,535,818	1,249,505	Aug 20 04:05 PM
Farwell Wildon	Officer	Aug 19 '24	Proposed Sale	45.12	2,321	104,718		Aug 19 04:13 PM
Scalzo Richard William	Officer	Aug 19 '24	Proposed Sale	45.12	2,752	124,163		Aug 19 04:12 PM
Beskrovnaya Oxana	Officer	Jun 11 '24	Proposed Sale	45.12	2,636	118,930		Aug 19 04:11 PM
McNeill Jonathan	Officer	Aug 19 '24	Proposed Sale	45.12	2,705	122,043		Aug 19 04:10 PM
HIGH SUSANNA GATTI	Officer	Aug 19 '24	Proposed Sale	45.12	2,910	131,292		Aug 19 04:08 PM
Kersten Dirk	Director	Aug 15 '24	Sale	45.37	180,891	8,206,150	1,372,148	Aug 16 04:05 PM
Kersten Dirk	Director	Aug 14 '24	Sale	43.67	100,650	4,395,386	1,553,039	Aug 16 04:05 PM
Kersten Dirk	Director	Aug 13 '24	Sale	42.78	133,985	5,731,742	1,653,689	Aug 14 04:15 PM
Kersten Dirk	Director	Aug 12 '24	Sale	43.19	78,492	3,390,160	1,787,674	Aug 14 04:15 PM
Kersten Dirk	Director	Aug 09 '24	Sale	42.96	92,164	3,959,145	6,232,959	Aug 12 04:05 PM
Kersten Dirk	Director	Aug 08 '24	Sale	42.74	91,670	3,917,946	6,325,123	Aug 12 04:05 PM
Forbion Capital Fund IV Cooper	Affiliate	Aug 08 '24	Proposed Sale	42.64	1,025,000	43,706,000		Aug 08 04:37 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Jun 21 '24	Option Exercise	5.54	29,787	165,020	178,579	Jun 24 08:41 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Jun 24 '24	Option Exercise	5.54	10,163	56,303	158,955	Jun 24 08:41 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Jun 21 '24	Sale	35.01	29,787	1,042,843	148,792	Jun 24 08:41 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Jun 24 '24	Sale	35.33	10,163	359,059	148,792	Jun 24 08:41 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Jun 12 '24	Option Exercise	5.54	40,000	221,600	188,792	Jun 13 09:45 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Jun 12 '24	Sale	33.36	40,000	1,334,201	148,792	Jun 13 09:45 PM
Beskrovnaya Oxana	Chief Scientific Officer	Jun 11 '24	Sale	31.34	2,136	66,942	147,511	Jun 11 07:42 PM
Farwell Wildon	Chief Medical Officer	Jun 11 '24	Sale	31.27	2,636	82,428	145,543	Jun 11 07:41 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Jun 10 '24	Option Exercise	5.54	80,000	443,200	234,062	Jun 11 07:34 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Jun 10 '24	Sale	30.24	80,000	2,419,200	154,062	Jun 11 07:34 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Jun 11 '24	Sale	31.23	5,270	164,582	148,792	Jun 11 07:34 PM
McNeill Jonathan	Chief Business Officer	Jun 11 '24	Sale	31.34	1,823	57,133	134,811	Jun 11 07:34 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Jun 10 '24	Sale	30.23	1,590	48,066	115,105	Jun 11 07:28 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Jun 11 '24	Sale	31.34	1,331	41,714	113,774	Jun 11 07:28 PM
Beskrovnaya Oxana	Chief Scientific Officer	May 20 '24	Option Exercise	1.03	30,426	31,339	180,073	May 22 09:01 PM
Beskrovnaya Oxana	Chief Scientific Officer	May 20 '24	Sale	32.96	30,426	1,002,751	149,647	May 22 09:01 PM
Beskrovnaya Oxana	Chief Scientific Officer	May 16 '24	Sale	28.27	2,705	76,469	149,647	May 17 09:07 PM
Farwell Wildon	Chief Medical Officer	May 16 '24	Sale	28.27	2,381	67,310	148,179	May 17 09:06 PM
HIGH SUSANNA GATTI	Chief Operating Officer	May 16 '24	Sale	28.27	2,738	77,402	154,062	May 17 09:05 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	May 16 '24	Sale	28.27	2,588	73,162	116,695	May 17 09:04 PM
McNeill Jonathan	Chief Business Officer	May 16 '24	Sale	28.27	2,774	78,420	136,634	May 17 09:03 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Mar 08 '24	Sale	26.67	27,199	725,344	159,092	Mar 13 06:04 AM
HIGH SUSANNA GATTI	Chief Operating Officer	Mar 11 '24	Sale	25.70	2,292	58,904	156,800	Mar 13 06:04 AM
McNeill Jonathan	Chief Business Officer	Mar 08 '24	Option Exercise	5.54	90,000	498,600	231,184	Mar 13 06:04 AM
McNeill Jonathan	Chief Business Officer	Mar 11 '24	Option Exercise	5.54	17,825	98,750	159,009	Mar 13 06:04 AM
McNeill Jonathan	Chief Business Officer	Mar 08 '24	Sale	26.24	90,000	2,361,531	141,184	Mar 13 06:04 AM
McNeill Jonathan	Chief Business Officer	Mar 11 '24	Sale	25.50	19,601	499,842	139,408	Mar 13 06:04 AM
Farwell Wildon	Chief Medical Officer	Mar 11 '24	Sale	25.70	1,585	40,734	151,590	Mar 12 09:58 PM
Farwell Wildon	Chief Medical Officer	Mar 12 '24	Sale	25.58	1,030	26,347	150,560	Mar 12 09:58 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 08 '24	Option Exercise	5.54	86,252	477,836	208,207	Mar 12 09:57 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 08 '24	Sale	26.22	86,252	2,261,465	121,955	Mar 12 09:57 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 11 '24	Sale	25.28	2,672	67,542	119,283	Mar 12 09:57 PM
Brumm Joshua T	CEO & President	Mar 08 '24	Option Exercise	5.54	363,343	2,012,920	917,728	Mar 12 09:56 PM
Brumm Joshua T	CEO & President	Mar 11 '24	Option Exercise	5.54	50,000	277,000	604,385	Mar 12 09:56 PM
Brumm Joshua T	CEO & President	Mar 08 '24	Sale	25.93	363,343	9,421,634	554,385	Mar 12 09:56 PM
Brumm Joshua T	CEO & President	Mar 11 '24	Sale	25.67	66,387	1,704,142	537,998	Mar 12 09:56 PM
Beskrovnaya Oxana	Chief Scientific Officer	Mar 11 '24	Sale	25.70	2,081	53,482	152,352	Mar 12 09:42 PM
Brumm Joshua T	CEO & President	Mar 07 '24	Sale	25.85	9,086	234,873	554,385	Mar 11 09:57 PM
Beskrovnaya Oxana	Chief Scientific Officer	Mar 07 '24	Sale	25.85	2,373	61,342	154,433	Mar 11 09:56 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Mar 07 '24	Sale	25.85	1,591	41,127	186,291	Mar 11 09:56 PM
Farwell Wildon	Chief Medical Officer	Mar 07 '24	Sale	25.86	9,921	256,585	153,175	Mar 11 09:52 PM
McNeill Jonathan	Chief Business Officer	Mar 07 '24	Sale	25.85	2,434	62,919	141,184	Mar 11 09:50 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 07 '24	Sale	25.85	2,273	58,757	121,955	Mar 11 09:45 PM
Rhodes Jason P	Director	Mar 01 '24	Sale	30.05	46,534	1,398,347	847,388	Mar 05 05:08 PM
Atlas Venture Opportunity Fund	10% Owner	Mar 01 '24	Sale	30.05	29,435	884,522	1,458,691	Mar 05 05:07 PM
Atlas Venture Opportunity Fund	10% Owner	Mar 01 '24	Sale	30.05	17,099	513,825	847,388	Mar 05 05:07 PM

KRRO

Korro Bio Inc.

DYN

Dyne Therapeutics Inc

Upgrade your FINVIZ experience